93879-40-4

Usage

Uses

Used in Pharmaceutical Industry:
(±)-N-3-Benzylnirvanol is used as an inhibitor of the cytochrome P450 isoform CYP2C19, playing a crucial role in the development of drugs targeting this specific isoform. Its ability to inhibit CYP2C19 can be beneficial in managing drug metabolism and interactions, potentially leading to improved therapeutic outcomes.
Used in Cholesterol Management:
In the field of cholesterol management, (±)-N-3-Benzylnirvanol is utilized for its cholesterol-lowering properties. (+/-)-N-3-Benzylnirvanol has demonstrated efficacy in reducing plasma cholesterol levels in mice, which could translate to potential applications in the treatment of hypercholesterolemia and related cardiovascular conditions in humans.

InChI:InChI=1/C18H18N2O2/c1-2-18(15-11-7-4-8-12-15)16(21)20(17(22)19-18)13-14-9-5-3-6-10-14/h3-12H,2,13H2,1H3,(H,19,22)

Upstream product

• 100-44-7 benzyl chloride 
• 2216-93-5 5-ethyl-5-phenyl-imidazolidine-2,4-dione 

Relevant academic research and scientific papers

New derivatives of hydantoin as potential antiproliferative agents: Biological and structural characterization in combination with quantum chemical calculations

Two new series of hydantoin derivatives, 3-(4-substituted benzyl)-5,5-diphenyl- and 3-(4-substituted benzyl)-5-ethyl-5-phenylhydantoins, were synthesized and their antiproliferative activity was tested against human colon cancer HCT-116 and breast cancer

Solvent effects on the structure-property relationship of some potentially pharmacologically active 3-(4-substituted benzyl)-5-ethyl-5-phenyl- and 3-(4-substituted benzyl)-5,5-diphenylhydantoins

Two series of 3-(4-substituted benzyl)-5-ethyl-5-phenyl- and 3-(4-substituted benzyl)-5,5-diphenylhydantoins were synthesized and their UV absorption spectra were recorded in the region 200-400 nm in selected solvents of different polarity. The effects of solvent dipolarity/polarizability and solvent/solute hydrogen bonding interactions on the spectral shifts were analyzed by means of the linear solvation energy relationship (LSER) methodology of Kamlet and Taft. The quantitative relationships between hydrogen bonding interactions and the lipophilicity and blood-brain permeation of the studied compounds were discussed. Satisfactory linear dependences were obtained for moderate electron-donating and electron-withdrawing substituents at the benzyl moiety, while the strong electron-withdrawing substituent (NO2) significantly modifies the solvation characteristics of the molecule. The paper clearly demonstrates how the solvatochromic comparison method may be applied to estimate the contributions of various modes of solvation to the pharmaceutically relevant properties of these newly synthetized hydantoin derivatives.